Sai Life Sciences Limited
Nippon India Mutual Fund increased its stake in Sai Life Sciences from 6.16% to 6.66% by purchasing 1,107,966 shares. This position increase is valued at approximately ₹157.57 crore based on the share price of ₹1422.20.
A contract research and manufacturing organization serving the pharmaceutical and biotechnology industries, Sai Life Sciences conducts research activities and produces customized solutions for clients globally. Incorporated in 1999, the company operates as a specialized service provider, offering integrated capabilities across drug development, formulation, and manufacturing to support its customers' product pipelines and commercial operations in India and international markets.
India's fifth-largest AMC with over Rs 6 lakh crore in AUM, backed by Japan's Nippon Life Insurance which holds majority stake. Formerly Reliance MF, rebranded in 2019 after Nippon's acquisition. Sailesh Raj Bhan has run the equity book for over two decades and is one of India's most experienced active managers. Known for sector rotational calls and a deep research bench.